数据显示，永赢基金旗下1只基金位居健尔康十大流通股东。医疗器械ETF（159883）三季度新进十大 流通股东，持有股数28.51万股，占流通股的比例为0.73%。根据测算，今日浮盈赚取约5.13万元。连续 6天上涨期间浮盈赚取55.88万元。 12月1日，健尔康涨0.63%，截至发稿，报28.66元/股，成交5043.53万元，换手率4.24%，总市值44.71亿 元。健尔康股价已经连续6天上涨，区间累计涨幅7.34%。 资料显示，健尔康医疗科技股份有限公司位于江苏省常州市金坛区直溪镇工业集中区健尔康路1号，成 立日期2000年6月6日，上市日期2024年11月7日，公司主营业务涉及医用敷料等一次性医疗器械及消毒 卫生用品研发、生产和销售。主营业务收入构成为：护理产品33.19%，手术耗材产品30.64%，高分子 及辅助类产品18.46%，消毒清洁产品16.93%，其他0.79%。 从健尔康十大流通股东角度 截至发稿，储可凡累计任职时间2年111天，现任基金资产总规模62.82亿元，任职期间最佳基金回报 103.17%， 任职期间最差基金回报-30.27%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型 ...

Group 1 - The core viewpoint of the news is that Jianerkang's stock performance and financial metrics indicate a decline in revenue and profit, alongside low financing levels and high short-selling ratios [1][2][3] Group 2 - On November 17, Jianerkang's stock fell by 1.01%, with a trading volume of 31.38 million yuan. The financing buy-in amount was 3.95 million yuan, while the net financing buy-in was 1.01 million yuan, indicating low investor confidence [1] - As of November 17, the total financing and securities lending balance for Jianerkang was 66.57 million yuan, with financing balance accounting for 5.67% of the circulating market value, which is below the 40th percentile of the past year [1] - The company reported a revenue of 725 million yuan for the first nine months of 2025, a year-on-year decrease of 7.35%, and a net profit of 76.41 million yuan, down 18.24% year-on-year [2] - Jianerkang's main business revenue composition includes nursing products (33.19%), surgical consumables (30.64%), polymer and auxiliary products (18.46%), and disinfection and cleaning products (16.93%) [1] - As of September 30, 2025, the number of shareholders for Jianerkang was 17,100, a decrease of 6.15%, while the average circulating shares per person increased by 38.51% to 2,286 shares [2] - The company has distributed a total of 42.12 million yuan in dividends since its A-share listing [3] - The largest circulating shareholder as of September 30, 2025, is the Medical Device ETF (159883), which holds 285,100 shares as a new shareholder [3]

Core Viewpoint - The company Jianerkang experienced a slight decline in stock price and reported specific financial metrics related to its trading activities and business performance [1][2]. Group 1: Trading Activity - On October 13, Jianerkang's stock price fell by 0.74%, with a trading volume of 23.36 million yuan [1]. - The financing buy-in amount for Jianerkang on the same day was 3.83 million yuan, while the financing repayment was 2.88 million yuan, resulting in a net financing buy-in of 0.95 million yuan [1]. - As of October 13, the total financing and securities lending balance for Jianerkang was 74.94 million yuan, with the financing balance accounting for 6.81% of the circulating market value [1]. Group 2: Company Overview - Jianerkang Medical Technology Co., Ltd. is located in Jintan District, Changzhou, Jiangsu Province, and was established on June 6, 2000, with its listing date set for November 7, 2024 [1]. - The company's main business involves the research, production, and sales of disposable medical devices and disinfectant hygiene products, with revenue composition as follows: nursing products 33.19%, surgical consumables 30.64%, polymer and auxiliary products 18.46%, disinfecting and cleaning products 16.93%, and others 0.79% [1]. Group 3: Financial Performance - As of June 30, Jianerkang had 18,200 shareholders, a decrease of 0.22% from the previous period, with an average of 1,650 circulating shares per person, an increase of 0.22% [2]. - For the first half of 2025, Jianerkang reported operating revenue of 466 million yuan, a year-on-year decrease of 7.60%, and a net profit attributable to shareholders of 48.15 million yuan, down 21.00% year-on-year [2]. - Since its A-share listing, Jianerkang has distributed a total of 42.12 million yuan in dividends [2].

Group 1 - The core viewpoint of the news is that Jianerkang experienced a decline in stock price and trading volume, with significant financing activities reported on September 2 [1] - On September 2, Jianerkang's stock fell by 2.13%, with a trading volume of 86.31 million yuan, and a net financing purchase of 2.67 million yuan [1] - As of September 2, the total balance of margin trading for Jianerkang was 93.78 million yuan, accounting for 7.93% of its market capitalization [1] Group 2 - As of June 30, Jianerkang had 18,200 shareholders, a decrease of 0.22% from the previous period, with an average of 1,650 circulating shares per shareholder, an increase of 0.22% [2] - For the first half of 2025, Jianerkang reported a revenue of 466 million yuan, a year-on-year decrease of 7.60%, and a net profit attributable to shareholders of 48.15 million yuan, down 21.00% year-on-year [2] Group 3 - Jianerkang has distributed a total of 42.12 million yuan in dividends since its A-share listing [3]